> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Abbisko’s pimicotinib wins FDA approval for TGCT
- URL: https://chinapharmadesk.com/abbisko-pimicotinib-fda-approval/
- Published: 2026-11-12T04:46:43.000Z
- Updated: 2026-11-13T10:46:14.000Z
- Description: FDA approved Abbisko (02256.HK) and Merck KGaA’s CSF-1R inhibitor pimicotinib (PIMJETMI / Beijiemai, NCT05804045) for adult TGCT after NMPA, Canada and Switzerland clearances.
- Author: Lin Yi
- Tags: Desk brief, Deals & BD, Regulation, Pipeline, Abbisko Therapeutics

**What moved.** Abbisko Therapeutics said the FDA approved pimicotinib (PIMJETMI / Beijiemai) for symptomatic tenosynovial giant cell tumor (TGCT) in adults where surgery may worsen function or cause serious complications, matching the U.S. regulator’s 10 Nov 2026 approval notice and Abbisko’s same-week Hong Kong filings.

**The number.** In the Phase 3 MANEUVER study ([NCT05804045](https://clinicaltrials.gov/study/NCT05804045?ref=chinapharmadesk.com)), blinded independent review by RECIST v1.1 at week 25 showed an objective response rate of **56%** on drug versus **3%** on placebo. Abbisko says this is the drug’s fourth major-market approval after China (Dec 2025), Canada (Jun 2026), and Switzerland (Oct 2026).

**Why it matters.** Global rights sit with Merck KGaA. A U.S. first commercial sale triggers another milestone for Abbisko, plus double-digit royalties on global net sales. For BD readers, this is a China-origin small molecule moving through a classic out-license path: local originator, multinational commercial owner, sequential major-market stamps.

*Related on China Pharma Desk:* [*Analysis: Abbisko’s staged $605.5m China-to-Merck licensing path*](https://chinapharmadesk.com/abbisko-pimicotinib-merck-deal-path/) *·* [*Analysis: Beijiemai’s China hospital launch and open NRDL question*](https://chinapharmadesk.com/abbisko-beijiemai-china-hospital-access/)